KRONOS BIO, INC.

Profile

Company Names

KRONOS BIO, INC.

Addresses

1300 S. EL CAMINO REAL, SUITE 300, SAN MATEO, CA 94402

689 FIFTH AVENUE, 12TH FLOOR, NEW YORK, NY 10022

Phone Numbers

212-871-7920

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2017

State Incorporated:

DELAWARE

Total Amount Raised:

$123,012,718.00

Number of Funding Rounds:

2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2019-07-01 
$105,000,005.00 
$105,000,005.00 
$0.00 
Equity 
1
2018-05-22 
$18,012,713.00 
$18,012,713.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
SEAN 
 
ALGEO 
EXECUTIVE OFFICER
KRONOS BIO, INC.   |  ICONOVIR BIO, INC.
ARIE 
S. 
BELLDEGRUN, M.D. 
DIRECTOR
HANA BIOSCIENCES INC   |  ARNO THERAPEUTICS, INC   |  KRONOS BIO, INC.
REBECKA 
 
BELLDEGRUN, M.D. 
DIRECTOR
KRONOS BIO, INC.
NORBERT 
 
BISCHOFBERGER, PH.D. 
EXECUTIVE OFFICER, DIRECTOR
KRONOS BIO, INC.
PHILIP 
 
GUTRY 
EXECUTIVE OFFICER
KRONOS BIO, INC.   |  GRAPHITE BIO, INC.
JOSHUA 
A. 
KAZAM 
DIRECTOR
NILE THERAPEUTICS, INC.   |  ARNO THERAPEUTICS, INC   |  KITE PHARMA, INC.   |  KIRAX CORP   |  VETERINARY PRIME, INC.   |  ALLOGENE THERAPEUTICS, INC.   |  KRONOS BIO, INC.   |  ICONOVIR BIO, INC.   |  BYHEART, INC.
JACOB 
 
LOVEN 
DIRECTOR
KRONOS BIO, INC.   |  NEXTECH VII ONCOLOGY SCSP   |  NEXTECH CROSSOVER I SCSP   |  NEXTECH VII CARRY SCSP   |  NEXTECH CROSSOVER I CARRY SCSP
JOHN 
C. 
MARTIN, PH.D. 
DIRECTOR
KRONOS BIO, INC.
OTELLO 
 
STAMPACCHIA, PH.D. 
DIRECTOR
GOSSAMER BIO, INC.   |  KRONOS BIO, INC.
DAVID 
M. 
TANEN 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
NILE THERAPEUTICS, INC.   |  ARNO THERAPEUTICS, INC   |  VETERINARY PRIME, INC.   |  ALLOGENE THERAPEUTICS, INC.   |  KRONOS BIO, INC.   |  NEOGENE THERAPEUTICS, INC.   |  ICONOVIR BIO, INC.
CHRISTOPHER 
 
WILFONG 
EXECUTIVE OFFICER
VERITAS GENETICS INTERNATIONAL LTD.   |  VETERINARY PRIME, INC.   |  KRONOS BIO, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2019-07-15
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-07-01 
2018-06-05
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-05-22 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#